keyword
https://read.qxmd.com/read/38712107/catalytically-distinct-idh1-mutants-tune-phenotype-severity-in-tumor-models
#1
Mowaffaq Adam Ahmed Adam, Mikella Robinson, Ashley V Schwartz, Grace Wells, An Hoang, Elene Albekioni, Grace Chao, Joi Weeks, Uduak Z George, Carrie D House, Şevin Turcan, Christal D Sohl
Mutations in isocitrate dehydrogenase 1 (IDH1) impart a neomorphic reaction that produces the oncometabolite D-2-hydroxyglutarate (D2HG), which can inhibit DNA and histone demethylases to drive tumorigenesis via epigenetic changes. Though heterozygous point mutations in patients primarily affect residue R132, there are myriad D2HG-producing mutants that display unique catalytic efficiency of D2HG production. Here, we show that catalytic efficiency of D2HG production is greater in IDH1 R132Q than R132H mutants, and expression of IDH1 R132Q in cellular and mouse xenograft models leads to higher D2HG concentrations in cells, tumors, and sera compared to R132H-expressing models...
April 23, 2024: bioRxiv
https://read.qxmd.com/read/38710674/active-site-remodeling-in-tumor-relevant-idh1-mutants-drives-distinct-kinetic-features-and-potential-resistance-mechanisms
#2
JOURNAL ARTICLE
Matthew Mealka, Nicole A Sierra, Diego Avellaneda Matteo, Elene Albekioni, Rachel Khoury, Timothy Mai, Brittany M Conley, Nalani J Coleman, Kaitlyn A Sabo, Elizabeth A Komives, Andrey A Bobkov, Andrew L Cooksy, Steve Silletti, Jamie M Schiffer, Tom Huxford, Christal D Sohl
Mutations in human isocitrate dehydrogenase 1 (IDH1) drive tumor formation in a variety of cancers by replacing its conventional activity with a neomorphic activity that generates an oncometabolite. Little is understood of the mechanistic differences among tumor-driving IDH1 mutants. We previously reported that the R132Q mutant unusually preserves conventional activity while catalyzing robust oncometabolite production, allowing an opportunity to compare these reaction mechanisms within a single active site...
May 6, 2024: Nature Communications
https://read.qxmd.com/read/38701786/molecular-glues-for-protein-protein-interactions-progressing-toward-a-new-dream
#3
REVIEW
Markella Konstantinidou, Michelle R Arkin
The modulation of protein-protein interactions with small molecules is one of the most rapidly developing areas in drug discovery. In this review, we discuss advances over the past decade (2014-2023) focusing on molecular glues (MGs)-monovalent small molecules that induce proximity, either by stabilizing native interactions or by inducing neomorphic interactions. We include both serendipitous and rational discoveries and describe the different approaches that were used to identify them. We classify the compounds in three main categories: degradative MGs, non-degradative MGs or PPI stabilizers, and MGs that induce self-association...
April 25, 2024: Cell Chemical Biology
https://read.qxmd.com/read/38583640/boosting-bdnf-in-muscle-rescues-impaired-axonal-transport-in-a-mouse-model-of-di-cmtc-peripheral-neuropathy
#4
JOURNAL ARTICLE
Elena R Rhymes, Rebecca L Simkin, Ji Qu, David Villarroel-Campos, Sunaina Surana, Yao Tong, Ryan Shapiro, Robert W Burgess, Xiang-Lei Yang, Giampietro Schiavo, James N Sleigh
Charcot-Marie-Tooth disease (CMT) is a genetic peripheral neuropathy caused by mutations in many functionally diverse genes. The aminoacyl-tRNA synthetase (ARS) enzymes, which transfer amino acids to partner tRNAs for protein synthesis, represent the largest protein family genetically linked to CMT aetiology, suggesting pathomechanistic commonalities. Dominant intermediate CMT type C (DI-CMTC) is caused by YARS1 mutations driving a toxic gain-of-function in the encoded tyrosyl-tRNA synthetase (TyrRS), which is mediated by exposure of consensus neomorphic surfaces through conformational changes of the mutant protein...
April 5, 2024: Neurobiology of Disease
https://read.qxmd.com/read/38571814/-apoe3-christchurch-modulates-%C3%AE-catenin-wnt-signaling-in-ips-cell-derived-cerebral-organoids-from-alzheimer-s-cases
#5
JOURNAL ARTICLE
Paula Perez-Corredor, Timothy E Vanderleest, Guido N Vacano, Justin S Sanchez, Nelson D Villalba-Moreno, Claudia Marino, Susanne Krasemann, Miguel A Mendivil-Perez, David Aguillón, Marlene Jiménez-Del-Río, Ana Baena, Diego Sepulveda-Falla, Francisco Lopera, Yakeel T Quiroz, Joseph F Arboleda-Velasquez, Randall C Mazzarino
A patient with the PSEN1 E280A mutation and homozygous for APOE3 Christchurch ( APOE3Ch ) displayed extreme resistance to Alzheimer's disease (AD) cognitive decline and tauopathy, despite having a high amyloid burden. To further investigate the differences in biological processes attributed to APOE3Ch , we generated induced pluripotent stem (iPS) cell-derived cerebral organoids from this resistant case and a non-protected control, using CRISPR/Cas9 gene editing to modulate APOE3Ch expression. In the APOE3Ch cerebral organoids, we observed a protective pattern from early tau phosphorylation...
2024: Frontiers in Molecular Neuroscience
https://read.qxmd.com/read/38559246/-idh-1-neomorphic-mutation-confers-sensitivity-to-vitamin-b12-via-increased-dependency-on-one-carbon-metabolism-in-caenorhabditis-elegans
#6
Olga Ponomarova, Alyxandra N Starbard, Alexandra Belfi, Amanda V Anderson, Meera V Sundaram, Albertha J M Walhout
The isocitrate dehydrogenase neomorphic mutation ( idh-1neo ) generates increased levels of cellular D-2-hydroxyglutarate (D-2HG), a proposed oncometabolite. However, the physiological effects of increased D-2HG and whether additional metabolic changes occur in the presence of an idh-1neo mutation are not well understood. We created a C. elegans model to study the effects of the idh-1neo mutation in a whole animal. Comparing the phenotypes exhibited by the idh-1neo to Δdhgd-1 (D-2HG dehydrogenase) mutant animals, which also accumulate D-2HG, we identified a specific vitamin B12 diet-dependent vulnerability in idh-1neo mutant animals that leads to increased embryonic lethality...
March 14, 2024: bioRxiv
https://read.qxmd.com/read/38559020/boosting-bdnf-in-muscle-rescues-impaired-axonal-transport-in-a-mouse-model-of-di-cmtc-peripheral-neuropathy
#7
Elena R Rhymes, Rebecca L Simkin, Ji Qu, David Villarroel-Campos, Sunaina Surana, Yao Tong, Ryan Shapiro, Robert W Burgess, Xiang-Lei Yang, Giampietro Schiavo, James N Sleigh
Charcot-Marie-Tooth disease (CMT) is a genetic peripheral neuropathy caused by mutations in many functionally diverse genes. The aminoacyl-tRNA synthetase (ARS) enzymes, which transfer amino acids to partner tRNAs for protein synthesis, represent the largest protein family genetically linked to CMT aetiology, suggesting pathomechanistic commonalities. Dominant intermediate CMT type C (DI-CMTC) is caused by YARS1 mutations driving a toxic gain-of-function in the encoded tyrosyl-tRNA synthetase (TyrRS), which is mediated by exposure of consensus neomorphic surfaces through conformational changes of the mutant protein...
March 11, 2024: bioRxiv
https://read.qxmd.com/read/38548315/subcellular-localisation-of-truncated-magel2-proteins-insight-into-the-molecular-pathology-of-schaaf-yang-syndrome
#8
JOURNAL ARTICLE
Mónica Centeno-Pla, Estefanía Alcaide-Consuegra, Sophie Gibson, Aina Prat-Planas, Juan Diego Gutiérrez-Ávila, Daniel Grinberg, Roser Urreizti, Raquel Rabionet, Susanna Balcells
Schaaf-Yang syndrome (SYS) is an ultra-rare neurodevelopmental disorder caused by truncating mutations in MAGEL2 Heterologous expression of wild-type (WT) or a truncated (p.Gln638*) C-terminal HA-tagged MAGEL2 revealed a shift from a primarily cytoplasmic to a more nuclear localisation for the truncated protein variant. We now extend this analysis to six additional SYS mutations on a N-terminal FLAG-tagged MAGEL2. Our results replicate and extend our previous findings, showing that all the truncated MAGEL2 proteins consistently display a predominant nuclear localisation, irrespective of the C-terminal or N-terminal position and the chemistry of the tag...
March 28, 2024: Journal of Medical Genetics
https://read.qxmd.com/read/38514345/-establishment-and-verification-of-invasion-syndrome-prediction-model-in-patients-with-diabetes-complicated-with-klebsiella-pneumoniae-liver-abscess
#9
JOURNAL ARTICLE
C Y Feng, L W Zhang, T Liu, S F Jiang, X M Li, J Di
Objective: To analyze the correlative factors of invasion syndrome in patients with diabetes complicated with Klebsiella pneumoniae liver abscess, and to construct and verify the online nomographic prediction model. Methods: A case control study. The clinical data of 213 diabetic patients with Klebsiella pneumoniae liver abscess admitted to the Third Affiliated Hospital of Soochow University from January 1, 2015 to December 31, 2021 were retrospectively analyzed. The patients were divided into the training set (149 cases) and the test set (64 cases) by stratified random sampling method at a ratio of 7∶3...
March 26, 2024: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://read.qxmd.com/read/38464189/active-site-remodeling-in-tumor-relevant-idh1-mutants-drives-distinct-kinetic-features-and-potential-resistance-mechanisms
#10
Christal Sohl, Matthew Mealka, Nicole Sierra, Diego Matteo, Elene Albekioni, Rachel Khoury, Timothy Mai, Brittany Conley, Nalani Coleman, Kaitlyn Sabo, Elizabeth Komives, Andrey Bobkov, Andrew Cooksy, Steve Silletti, Jamie Schiffer, Tom Huxford
Mutations in human isocitrate dehydrogenase 1 (IDH1) drive tumor formation in a variety of cancers by replacing its conventional activity with a neomorphic activity that generates an oncometabolite. Little is understood of the mechanistic differences among tumor-driving IDH1 mutants. We previously reported that the R132Q mutant uniquely preserves conventional activity while catalyzing robust oncometabolite production, allowing an opportunity to compare these reaction mechanisms within a single active site. Here, we employed static and dynamic structural methods and found that, compared to R132H, the R132Q active site adopted a conformation primed for catalysis with optimized substrate binding and hydride transfer to drive improved conventional and neomorphic activity over R132H...
February 23, 2024: Research Square
https://read.qxmd.com/read/38413794/spontaneous-expression-of-the-cic-dux4-fusion-oncoprotein-from-a-conditional-allele-potently-drives-sarcoma-formation-in-genetically-engineered-mice
#11
JOURNAL ARTICLE
Peter G Hendrickson, Kristianne M Oristian, MaKenna R Browne, Lixia Luo, Yan Ma, Diana M Cardona, Joshua O Nash, Pedro L Ballester, Scott Davidson, Adam Shlien, Corinne M Linardic, David G Kirsch
CIC::DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no effective treatments and efforts to identify and translate better therapies are limited by the scarcity of patient tumor samples and cell lines. To address this limitation, we generated three genetically engineered mouse models of CDS (Ch7CDS, Ai9CDS, and TOPCDS). Remarkably, chimeric mice from all three conditional models developed spontaneous soft tissue tumors and disseminated disease in the absence of Cre-recombinase...
February 27, 2024: Oncogene
https://read.qxmd.com/read/38288683/de-novo-variants-in-sp9-cause-a-novel-form-of-interneuronopathy-characterized-by-intellectual-disability-autism-spectrum-disorder-and-epilepsy-with-variable-expressivity
#12
JOURNAL ARTICLE
Marine Tessarech, Gaëlle Friocourt, Florent Marguet, Maryline Lecointre, Morgane Le Mao, Rodrigo Muñoz Díaz, Cyril Mignot, Boris Keren, Bénédicte Héron, Charlotte De Bie, Koen Van Gassen, Didier Loisel, Benoit Delorme, Steffen Syrbe, Annick Klabunde-Cherwon, Rami Abou Jamra, Meret Wegler, Bert Callewaert, Annelies Dheedene, Merzouka Zidannes-Marinnes, Agnès Guichet, Céline Bris, Patrick Van Bogaert, Florence Biquard, Guy Lenaers, Pascale Marcorelles, Claude Ferec, Bruno Gonzalez, Vincent Procaccio, Antonio Vitobello, Dominique Bonneau, Annie Laquerriere, Salim Khiati, Estelle Colin
PURPOSE: Interneuronopathies are a group of neurodevelopmental disorders characterized by deficient migration and differentiation of GABAergic interneurons resulting in a broad clinical spectrum, including autism spectrum disorders, early-onset epileptic encephalopathy, intellectual disability, and schizophrenic disorders. SP9 is a transcription factor belonging to the Krüppel-like factor and specificity protein family, the members of which harbor highly conserved DNA binding domains...
January 27, 2024: Genetics in Medicine: Official Journal of the American College of Medical Genetics
https://read.qxmd.com/read/38260668/active-site-remodeling-in-idh1-mutants-drives-distinct-kinetic-and-potential-resistance-mechanisms
#13
Matthew Mealka, Nicole A Sierra, Diego Avellaneda Matteo, Elene Albekioni, Rachel Khoury, Timothy Mai, Brittany M Conley, Nalani J Coleman, Kaitlyn A Sabo, Elizabeth A Komives, Andrey A Bobkov, Andrew L Cooksy, Steve Silletti, Jamie M Schiffer, Tom Huxford, Christal D Sohl
Human isocitrate dehydrogenase 1 (IDH1) is a highly conserved enzyme that converts isocitrate to α-ketoglutarate (αKG). IDH1 mutations affecting residue R132 drive tumor formation, and several FDA-approved mutant IDH1 inhibitors are available. Most mutants cannot catalyze the conventional reaction, but gain a neomorphic activity that produces D-2-hydroxyglutarate (D2HG). We previously reported that IDH1 R132Q uniquely preserves conventional activity while catalyzing robust D2HG production, allowing an opportunity to compare these reaction mechanisms within a single active site...
January 11, 2024: bioRxiv
https://read.qxmd.com/read/38201282/deciphering-acute-myeloid-leukemia-associated-transcription-factors-in-human-primary-cd34-hematopoietic-stem-progenitor-cells
#14
REVIEW
Sophie Kreissig, Roland Windisch, Christian Wichmann
Hemato-oncological diseases account for nearly 10% of all malignancies and can be classified into leukemia, lymphoma, myeloproliferative diseases, and myelodysplastic syndromes. The causes and prognosis of these disease entities are highly variable. Most entities are not permanently controllable and ultimately lead to the patient's death. At the molecular level, recurrent mutations including chromosomal translocations initiate the transformation from normal stem-/progenitor cells into malignant blasts finally floating the patient's bone marrow and blood system...
December 29, 2023: Cells
https://read.qxmd.com/read/38105987/-sirt5-variants-from-patients-with-mitochondrial-disease-are-associated-with-reduced-sirt5-stability-and-activity-but-not-with-neuropathology
#15
Taolin Yuan, Surinder Kumar, Mary Skinner, Ryan Victor-Joseph, Majd Abuaita, Jaap Keijer, Jessica Zhang, Thaddeus J Kunkel, Yanghan Liu, Elyse M Petrunak, Thomas L Saunders, Andrew P Lieberman, Jeanne A Stuckey, Nouri Neamati, Fathiya Al-Murshedi, Majid Alfadhel, Johannes N Spelbrink, Richard Rodenburg, Vincent C J de Boer, David B Lombard
SIRT5 is a sirtuin deacylase that represents the major activity responsible for removal of negatively-charged lysine modifications, in the mitochondrial matrix and elsewhere in the cell. In benign cells and mouse models, under basal non-stressed conditions, the phenotypes of SIRT5 deficiency are generally quite subtle. Here, we identify two homozygous SIRT5 variants in human patients suffering from severe mitochondrial disease. Both variants, P114T and L128V, are associated with reduced SIRT5 protein stability and impaired biochemical activity, with no evidence of neomorphic or dominant negative properties...
December 8, 2023: bioRxiv
https://read.qxmd.com/read/38018114/from-teeth-to-pad-tooth-loss-and-development-of-keratinous-structures-in-sirenians
#16
JOURNAL ARTICLE
Lionel Hautier, Helder Gomes Rodrigues, Sérgio Ferreira-Cardoso, Christopher A Emerling, Marie-Lou Porcher, Robert J Asher, Roberto Portela Miguez, Frédéric Delsuc
Sirenians are a well-known example of morphological adaptation to a shallow-water grazing diet characterized by a modified feeding apparatus and orofacial morphology. Such adaptations were accompanied by an anterior tooth reduction associated with the development of keratinized pads, the evolution of which remains elusive. Among sirenians, the recently extinct Steller's sea cow represents a special case for being completely toothless. Here, we used μ-CT scans of sirenian crania to understand how motor-sensor systems associated with tooth innervation responded to innovations such as keratinized pads and continuous dental replacement...
November 29, 2023: Proceedings. Biological Sciences
https://read.qxmd.com/read/37961185/expression-of-the-cic-dux4-fusion-oncoprotein-mimics-human-cic-rearranged-sarcoma-in-genetically-engineered-mouse-models
#17
David Kirsch, Peter Hendrickson, Kristianne Oristian, MaKenna Browne, Lixia Lou, Yan Ma, Dianna Cardona, Corinne Linardic
CIC-DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no effective treatments and efforts to identify and translate better therapies are limited by the scarcity of patient tumor samples and cell lines. To address this limitation, we generated three genetically engineered mouse models of CDS (Ch7CDS, Ai9CDS, and TOPCDS). Remarkably, chimeric mice from all three conditional models developed spontaneous tumors and widespread metastasis in the absence of Cre-recombinase...
October 29, 2023: Research Square
https://read.qxmd.com/read/37935654/transcriptional-reprogramming-by-mutated-irf4-in-lymphoma
#18
JOURNAL ARTICLE
Nikolai Schleussner, Pierre Cauchy, Vedran Franke, Maciej Giefing, Oriol Fornes, Naveen Vankadari, Salam A Assi, Mariantonia Costanza, Marc A Weniger, Altuna Akalin, Ioannis Anagnostopoulos, Thomas Bukur, Marco G Casarotto, Frederik Damm, Oliver Daumke, Benjamin Edginton-White, J Christof M Gebhardt, Michael Grau, Stephan Grunwald, Martin-Leo Hansmann, Sylvia Hartmann, Lionel Huber, Eva Kärgel, Simone Lusatis, Daniel Noerenberg, Nadine Obier, Ulrich Pannicke, Anja Fischer, Anja Reisser, Andreas Rosenwald, Klaus Schwarz, Srinivasan Sundararaj, Andre Weilemann, Wiebke Winkler, Wendan Xu, Georg Lenz, Klaus Rajewsky, Wyeth W Wasserman, Peter N Cockerill, Claus Scheidereit, Reiner Siebert, Ralf Küppers, Rudolf Grosschedl, Martin Janz, Constanze Bonifer, Stephan Mathas
Disease-causing mutations in genes encoding transcription factors (TFs) can affect TF interactions with their cognate DNA-binding motifs. Whether and how TF mutations impact upon the binding to TF composite elements (CE) and the interaction with other TFs is unclear. Here, we report a distinct mechanism of TF alteration in human lymphomas with perturbed B cell identity, in particular classic Hodgkin lymphoma. It is caused by a recurrent somatic missense mutation c.295 T > C (p.Cys99Arg; p...
November 7, 2023: Nature Communications
https://read.qxmd.com/read/37902300/leveraging-ligand-affinity-and-properties-discovery-of-novel-benzamide-type-cereblon-binders-for-the-design-of-protacs
#19
JOURNAL ARTICLE
Christian Steinebach, Aleša Bricelj, Arunima Murgai, Izidor Sosič, Luca Bischof, Yuen Lam Dora Ng, Christopher Heim, Samuel Maiwald, Matic Proj, Rabea Voget, Felix Feller, Janez Košmrlj, Valeriia Sapozhnikova, Annika Schmidt, Maximilian Rudolf Zuleeg, Patricia Lemnitzer, Philipp Mertins, Finn K Hansen, Michael Gütschow, Jan Krönke, Marcus D Hartmann
Immunomodulatory imide drugs (IMiDs) such as thalidomide, pomalidomide, and lenalidomide are the most common cereblon (CRBN) recruiters in proteolysis-targeting chimera (PROTAC) design. However, these CRBN ligands induce the degradation of IMiD neosubstrates and are inherently unstable, degrading hydrolytically under moderate conditions. In this work, we simultaneously optimized physiochemical properties, stability, on-target affinity, and off-target neosubstrate modulation features to develop novel nonphthalimide CRBN binders...
October 30, 2023: Journal of Medicinal Chemistry
https://read.qxmd.com/read/37808628/expression-of-the-cic-dux4-fusion-oncoprotein-mimics-human-cic-rearranged-sarcoma-in-genetically-engineered-mouse-models
#20
Peter G Hendrickson, Kristianne M Oristian, MaKenna R Browne, Lixia Lou, Yan Ma, Dianna M Cardona, Corinne M Linardic, David G Kirsch
CIC-DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no effective treatments and efforts to identify and translate better therapies are limited by the scarcity of tissues and patients. To address this limitation, we generated three genetically engineered mouse models of CDS (Ch7CDS, Ai9CDS, and TOPCDS). Remarkably, chimeric mice from all three conditional models developed spontaneous tumors and widespread metastasis in the absence of Cre-recombinase...
September 28, 2023: bioRxiv
keyword
keyword
38096
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.